CA2466720C - Medicament for the treatment of viral skin and tumour diseases - Google Patents
Medicament for the treatment of viral skin and tumour diseases Download PDFInfo
- Publication number
- CA2466720C CA2466720C CA2466720A CA2466720A CA2466720C CA 2466720 C CA2466720 C CA 2466720C CA 2466720 A CA2466720 A CA 2466720A CA 2466720 A CA2466720 A CA 2466720A CA 2466720 C CA2466720 C CA 2466720C
- Authority
- CA
- Canada
- Prior art keywords
- gallate
- epigallocatechol
- epicatechol
- gallocatechol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The invention relates to a medicament containing a compound of general formula (I), where R1 = independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2 = independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a -[CH2-(CH2)m-O]nH group with n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2-[CH-(OH)]p [CH2-(R3)]- group, where R3 = independently H or OH, p = 1 to 7, preferably p = 1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumour diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.
Description
Medicament for the treatment of viral skin and tumour diseases The present invention relates to a pharmaceutical which comprises a compound of the formula O
where R1, independent of each other, is an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl radical, preferably a C11-Cls alkyl, alkylene or alkynyl radical, in particular a C11-C13 alkyl, alkylene or alkynyl radical, especially a C13-alkyl radical, and R2 is, independent of each other, an unbranched or branched C1-CB alkyl, alkylene or alkynyl radical, preferably a C1-C6 alkyl, alkylene or alkynyl radical, in particular a C2-C4 alkyl, alkylene or alkynyl radical, especially a C3-alkyl radical, a-[CH2- (CHz)n,-O]õ-H radical where n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2- [CH- (OH) ] P- (CH2- (R3) ] radical, where R3 is, independent of each other, a hydrogen or a hydroxyl radical, p = 1 to 7, preferably p = 1 to 4, a pentose radical or a hexose radical, as a therapeutically active compound, either alone or together with one or more additional pharmaceutical active compounds as a combination preparation, for treating viral skin diseases and/or tumor diseases which are caused, in particular, by human papilloma viruses (HPV) and/or herpes viruses, and also to a
where R1, independent of each other, is an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl radical, preferably a C11-Cls alkyl, alkylene or alkynyl radical, in particular a C11-C13 alkyl, alkylene or alkynyl radical, especially a C13-alkyl radical, and R2 is, independent of each other, an unbranched or branched C1-CB alkyl, alkylene or alkynyl radical, preferably a C1-C6 alkyl, alkylene or alkynyl radical, in particular a C2-C4 alkyl, alkylene or alkynyl radical, especially a C3-alkyl radical, a-[CH2- (CHz)n,-O]õ-H radical where n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2- [CH- (OH) ] P- (CH2- (R3) ] radical, where R3 is, independent of each other, a hydrogen or a hydroxyl radical, p = 1 to 7, preferably p = 1 to 4, a pentose radical or a hexose radical, as a therapeutically active compound, either alone or together with one or more additional pharmaceutical active compounds as a combination preparation, for treating viral skin diseases and/or tumor diseases which are caused, in particular, by human papilloma viruses (HPV) and/or herpes viruses, and also to a
- 2 -topically acting pharmaceutical formulation and its use.
Papilloma viruses (HPV) are DNA viruses which infect the epithelial cells of mammals and thereby induce uncontrolled cell growth. There are a very wide variety of papilloma viruses, which infect humans and different animal species. In this connection, all the viral types infect the basal epithelial cells and remain as episomes or integrate their DNA into the host genome.
It has been known for a long time that papilloma viruses cause genital warts (Condyloma acuminata), ordinary and plantar warts, bowenoid papulosis in men and women, and cervical intraepithelial neoplasias in women.
Depending on the method used, the detection rate for HPV is almost 100%. It is in the main HPV 6 and HPV 11 viruses which are found in warts and genital warts (Condyloma acuminata). Since HPV 16 and HPV 18 are principally observed in malignant, desquamative cell carcinomas, as in the case of cancer of the penis and of the uterine cervix, it is generally accepted that HPV 16 and HPV 18 are linked to malignant HPV diseases.
At present, physical methods are predominantly used for treating genital warts caused by human papilloma viruses. These methods include surgical removal, electrocauterization, cryosurgery and laser therapy to mention but a few. An additional medicinal treatment is the use of Podophyllin, 5-Fluorouracil, Bleomycin, Interferon, Imiquimod, etc.
Surgical treatment suffers from the disadvantage that it is very unpleasant for the patient and can lead to further infection. Up until now, a topical use has _ 3 _ involved the risk of side effects since the active compounds employed possess cytotoxic properties or augment the cellular immune defense and can consequently induce local inflammations. This demonstrates that the therapeutic possibilities which have thus far been available are still not satisfactory.
In addition to this, there is the fact that the proportion of recurrences is very high in the case of warts and genital warts and complete healing can only be achieved by means of constant and consistent treatment. For this reason, there is a need for a more reliable and comfortable treatment.
Particularly when treating genital warts, but also in connection with all the other diseases which are caused by the papilloma virus, there is a requirement for a treatment which is easy for the patient to use. For example, a treatment which the patient himself can use at the affected sites and which gives good results in relatively short time, and exhibits only few or no side effects, would be suitable.
Herpes simplex viruses (HSV) are DNA viruses from the alpha subfamily Herpetoviridae. They are divided into two groups, i.e. HSV 1, termed the oral strain, and HSV 2, termed the genital strain. Herpes simplex viruses penetrate, as a nucleocapsid, into the nerve endings and, using the axonal flow, reach the appurtenant ganglia. They are transmitted by smear and droplet infection from herpes lesions or by healthy chronic carriers. Following a primary infection, the viruses can be reactivated once again, symptomatically or asymptomatically, by irritation, for example due to fever, trauma or radiation, of latently infected neurons. This reactivation depends, in particular, on the defensive condition of the body taken as a whole.
Herpes simplex viruses can transform cells neoplastically in animals and in cell cultures. The possibility of an interaction between type 2 herpes simplex viruses and the genesis of cervical carcinomas involving type 16 and type 18 human papilloma viruses is presently being discussed.
EP 0 087 161 discloses treating herpes infections by treating them with a mixture consisting of isopropyl myristate and small quantities of 4-{lower alkyl}-2,6-(bis-tert-butyl)phenol containing 2,6-(bis-tert-butyl)-4-hydroxytoluene or 4-(lower alkyl)-2,6-(bis-tert-butyl)phenol.
EP 0 842 660 describes a pharmaceutical composition for treating genital warts which are caused by human papilloma viruses. The composition which is described comprises catechols from tea extracts (Camellia sinensis), predominantly (-)-epigallocatechol-gallate in the form of an ointment or a suppository.
An object of the present invention is therefore to find additional effective antiviral substances and formulations which are suitable for treating viral skin diseases and/or tumor diseases which are caused by papilloma viruses and/or herpes viruses.
It has now been found, surprisingly, that a pharmaceutical which comprises,a compound according to the invention of the formula (I) as the pharmaceuticall.y active compound is suitable for treating viral skin diseases and/or tumor diseases.
The present invention consequently relates to a pharmaceutical which comprises a compound of the formula (I) as the pharmaceutically active compound, A - B
(I) where A is a radical of the formula (II) Ri (II) and B is a radical of the formula (III) (III), and R1 is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl radical, preferably a C11-C15 alkyl, alkylene or alkynyl radical, in particular a C11-C13 alkyl, alkylene or alkynyl radical, especially a C13-alkyl radical, and R2 is, independent of each other, an unbranched or branched C1-C8 alkyl alkylene or alkynyl radical, preferably a C1-C6 alkyl, alkylene or alkynyl radical, in particular a C2-C4 alkyl, alkylene or alkynyl radical, especially a C3 alkyl radical, a-[CH2- (CH2) m O]õ-H radical where n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2- [CH- (OH) ] p- (CH2- (R3) ] radical, where R3 is, independent of each other, a hydrogen or a hydroxyl radical, p = 1 to 7, preferably p= 1 to 4, a pentose radical or a hexose radical.
- 5a -The invention further relates to a use of a compound of the formula (I) A - B
(I) and at least one catechol of the formula (IV) OH
HO O OH
URa R
(IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) oN
OH
O
OH
(V) characterized in that in formula (I) A is a radical of the formula (II) l I
Ri (II) -5b-and B is a radical of the formula (III) (III) , and Rl is a C13-alkyl radical, R2 is selected from:
(a) an unbranched or branched C1-C8alkyl, alkylene or alkynyl radical, (b) a -[CHz-(CH2) m-0] n-H radical, wherein n = 1 to 10 and m= 1 to 5, (c) a -CH2- [CH- (OH) ] p- (CHz- (R3) ] radical, wherein R3 is selected from a hydrogen and a hydroxyl radical, and p= 1 to 7, (d) a pentose radical, and (e) a hexose radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
The invention further relates to a use of a composition comprising a compound of the formula (I) A-B
(I) and at least one catechol of the formula (IV) OH
HO OH
H
(IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) O}l OH
OH
(V) characterized in that in formula (I) A is a radical of the formula (II) il Ri (II) and B is a radical of the formula (III) (III), and -5d-R1 is an unsubstituted or substituted C13-alkyl radical, R2 is an unsubstituted or substituted, unbranched or branched, Cl-Csalkyl, alkylene or alkynyl radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
In this connection, the radical R1 and/or the radical R2 can, independent of each other, be substituted by a halogen, preferably fluorine and/or chlorine, or an unbranched or branched C1.-C6 alkyl, alkylene or alkynyl radical, preferably a C1-C3 alkyl, alkylene or alkynyl radical, in particular a methyl radical.
In this connection, the radical A of the compound (I) can, for example, be derived from hexanoic acid (caproic acid), heptanoic acid, octanoic acid (caprylic acid), nonanoic acid, decanoic acid (capric acid), undecanoic acid, dodecanoic acid (lauric acid), tridecanoic acid, tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid, octadecanoic acid (stearic acid), nonadecanoic acid, eicosanoic acid, heneicosanoic acid, oleic acid, linoleic acid, linolenic acid and/or arachidonic acid, preferably from caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid and/or arachidonic acid, particularly preferably from myristic acid.
The radical B of the compound (I) can, for example, be derived from an unbranched or branched C1-C8 alkyl alcohol, in particular ethanol, propanol, isopropanol, n-butanol, tert-butanol, particularly preferably isopropanol, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, polyglycerol, a pentose sugar, such as arabitol, adonitol and xylitol, or a hexose sugar, such as sorbitol, mannitol or dulcitol, preferably from ethanol, propanol, isopropanol, butanol, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, polyglycerol, arabitol, adonitol, xylitol, sorbitol, mannitol and/or dulcitol.
The compound (I) is preferably isopropyl laureate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, ethyl myristate, propyl myristate, butyl myristate and/or ethyl oleate, in particular isopropyl myristate.
In another preferred embodiment, the compound (I) is a hydrophobic compound. According to the present invention, a hydrophobic compound is understood as being a compound whose solubility in water is at most approx. 0.2 mg/ml, in particular at most approx.
0.1 mg/ml.
The pharmaceutical comprises, for example, at least approx. 5% - 75% (w/w), preferably at least approx. 10%
- 60% (w/w), in particular at least approx. 25% - 55%
(w/w) , and especially at least approx. 35 0- 50 0(w/w) of the compound of the formula (I).
In this connection, the pharmaceutical according to the invention can also contain one or more additional pharmaceutical active compounds as a combination preparation for use which is simultaneous, separate or staggered in time. In this context, preference is given to employing, as additional pharmaceutical active compounds, those compounds which can be used for treating viral skin diseases and/or tumor diseases, such as podophyllin, 5-fluorouracil, bleomycin, interferon or imiquimod, and/or mixtures which comprise at least one catechol.
In a preferred embodiment, the additional pharmaceutical active compound is an amphiphilic or amphipathic active compound. An amphiphilic or amphipathic active compound is understood as being an active compound which is composed of two functional moieties, in particular one hydrophilic moiety and one lipophilic moiety. This property might, in particular, be able to facilitate the passage of the substance through the skin and achieve an improved effect. In this connection, the improved effect may be attributable, for example, to a longer dwell time at the desired site or to a reduction in the dose of the active compound.
In a further preferred embodiment, the additional pharmaceutical active compound comprises at least one catechol of the formula (IV) Uti tio o (IV) in which R3 is -H or -OH, and R4 is -H or a group of the formula (V) OH
OH
O
OH
(V) The catechols which are added in this connection may be obtained either synthetically or from natural sources.
The natural sources which may especially be mentioned are tea plants. In this context, the natural constituents may bepresent in differing concentrations depending on the species and variety. In this connection, the catechols which are employed are preferably isolated from Camellia sinensis, Camellia asamica, Camellia bohea, Camellia chinensis or Camellia oleosa. All the components of tea plants, in particular the leaves, can be used for isolating the catechols.
The catechols which are employed are preferably isolated from a tea extract.
The catechols which are employed in the present invention are preferably epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, gallocatechol and gallocatechol gallate, in particular (-)-epicatechol, (-)-epicatechol gallate, epigallocatechol, (-)-epigallocatechol gallate, (+)-gallocatechol and (-)-gallocatechol gallate.
The catechols can be used both individually and in the form of mixtures having different compositions. A
catechol mixture contains approx. 2-20% (w/w), preferably approx. 4-15% (w/w), in particular approx.
10-11% (w/w) of (-)-epicatechol, approx. 2-20% (w/w), preferably approx. 5-15% (w/w), in particular approx.
5-7% (w/w) of (-)-epicatechol gallate, approx. 1-25%
(w/w), preferably approx. 3-15% (w/w), in particular approx. 5-7% (w/w) of (-)-epigallocatechol, approx. 40-75% (w/w), preferably approx. 57-67% (w/w), in particular approx. 61-66% (w/w) of (-)-epigallocatechol gallate, approx. 0.05-5% (w/w), preferably approx. 0.1-1% (w/w), in particular approx. 0.1-0.6% (w/w) of (+)-gallocatechol and/or approx. 0.5-20% (w/w), preferably approx. 1-10% (w/w), in particular approx. 1-5% (w/w) of (-)-gallocatechol gallate.
In a preferred embodiment, the catechol mixture is composed of approx. 5.9% (w/w) of (-)-epicatechol, approx. 12.6% (w/w) of (-)-epicatechol gallate, approx.
17.6% (w/w) of (-)-epigallocatechol, approx. 53.9%
(w/w) of (-)-epigallocatechol gallate and/or approx.
1.4% (w/w) of (-)-gallocatechol. A composition of this nature is known under the name Polyphenon 100.
In a particularly preferred embodiment, the catechol mixture is composed of approx. 10.8% (w/w) of (-)-epicatechol, approx. 6.5% (w/w) of (-)-epicatechol gallate, approx. 9.2% (w/w) of (-)-epigallocatechol, approx. 54.8% (w/w) of (-)-epigallocatechol gallate and/or approx. 4.0% (w/w) of (-)-gallocatechol gallate.
A composition of this nature is known under the name Polyphenon E.
The pharmaceutical according to the invention comprises, for example, approx. 1-30% (w/w), preferably approx. 2-20% (w/w) and, in particular, approx. 15-18%
(w/w) of a catechol and at least approx. 5-90% (w/w), preferably at least approx. 10-70% (w/w), in particular at least approx. 25-60% (w/w) and, especially, at least approx. 35-50% (w/w) of the compound (I).
The familiar methods of pharmaceutical technology are used, in a customary manner, for preparing pharmaceuticals which comprise one or more compounds according to the invention and/or for using these pharmaceuticals in the application according to the invention. For this, the active compounds are worked up, together with suitable, pharmaceutically acceptable auxiliary substances and carrier substances, into the medicinal forms which are suitable for the different indications and sites of administration. In this context, the pharmaceuticals can be prepared such that the rate of release in each case desired, for example a rapid accumulation and/or a delayed-release or depot effect, is achieved.
Customary emulsions, gels, ointments, creams of the mixed-phase or amphiphilic emulsion systems (oil/water-' - 11 -water/oil mixed phase), and also liposomes and transfersomes or plasters, preferably ointments and creams, particularly preferably an ointment, may be mentioned for conventional application to the skin or mucosa. The active compound is preferably applied locally in the region in which there is a skin or mucosal change and/or disease.
In addition to the known uses on the skin and/or mucosa, the following are suitable for use as special pharmaceutical preparations which can be administered topically, locally or regionally: emulsions, creams, ointments, effervescent tablets or suppositories which can be administered genitally, vaginally or rectally, in particular genitally and vaginally. Rectal capsules can also be prepared on the basis of gelatin or other carrier substances. Suitable suppository bases are hardened fats, such as Witepsol , Massa Estarium , Novata , coconut butter, glycerol/gelatin pastes, glycerol/soap gels and polyethylene glycols.
Examples of suitable auxiliary and/or carrier substances are sodium alginate, as a gelatinizing agent for preparing a suitable base, or cellulose derivatives, such as guar or xanthan gum, inorganic gelatinizing agents, such as aluminum hydroxide or bentonites (what are termed thixotropic gel-formers), polyacrylic acid derivatives, such as Carb.opol , polyvinylpyrrolidone, microcrystalline cellulose and carboxymethylcellulose. Amphiphilic low molecular weight and higher molecular weight compounds, and also phospholipids, are also suitable. The gels can be present either as water-based hydrogels or as hydrophobic organogels, for example based on mixtures of low and high molecular weight paraffin hydrocarbons and vaselineT"'. The hydrophilic organogels can be prepared, for example, on the basis of high molecular weight polyethylene glycols. These gelatinous forms are washable. However, the organogels which are preferred are the hydrophobic organogels. Particular preference is given to hydrophobic auxiliary substances and additives, such as petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate and propylene glycol monopalmitostearate. It is, of course, likewise possible to add skin-sedating and/or inflammation-inhibiting additives which are known to the skilled person, such as synthetically prepared active compounds and/or extracts and/or active compounds from medicinal plants, in particular bisobolol and panthenol. It is furthermore also possible to add dyes, for example yellow and/or red iron oxide and/or titanium dioxide for the purpose of matching as regards color.
Emulsifiers which can be employed are anionic, cationic or neutral surfactants, for example alkali metal soaps, metal soaps, amine soaps, sulfonated compounds, invert soaps, higher fatty alcohols, partial fatty acid esters of sorbitan and polyoxyethylene sorbitan, e.g. lanette types, wool wax, lanolin or other synthetic products for preparing the oil/water and/or water/oil emulsions.
It is possible to use vaselineT"', natural or synthetic waxes, fatty acids, fatty alcohols, fatty acid esters, for example as monoglycerides, diglycerides or triglycerides, paraffin oil or vegetable oils, hydrogenated castor oil or coconut oil, hog fat, synthetic fats, for example based on, caprylic acid, capric acid, lauric acid or stearic acid, such as Softisan , or triglyceride mixtures, such as Miglyol , can be used as lipids, in the form of fatty and/or oleaginous and/or waxy components for preparing the ointments, creams or emulsions.
It is possible to use, for example, osmotically active acids and alkaline solutions, for example hydrochloric acid, citric acid, sodium hydroxide solution, potassium hydroxide solution, sodium hydrogen carbonate, and, in addition, buffer systems, such as citrate, phosphate, tris buffer or triethanolamine, for adjusting the pH.
It is possible to add preservatives as well, such as methyl benzoate or propyl benzoate (parabens) or sorbic acid, for increasing the stability.
Pastes, powders and solutions may be mentioned as additional forms which can be applied topically. As consistency-imparting bases, the pastes frequently contain hydrophobic and hydrophilic auxiliary substances, preferably, however, hydrophobic auxiliary substances containing a very high proportion of solids.
In order to increase dispersity, and also flowability and slipperiness, and also to prevent agglomerates, the powders or topically applicable powders can, for example, contain starch species, such as wheat or rice starch, flame-dispersed silicon dioxide or siliceous earth, which also serve as diluent.
The medicinal forms which are in each case suitable can be produced on the basis of pharmaceutico-physical principles in conformity with formulation guidelines and methods known to a skilled person.
The pharmaceutical according to the invention preferably comprises approx. 35% (w/w) of isopropyl myristate, approx. 15% (w/w) of at least one catechol, approx. 24.5% (w/w) of petroleum jelly, approx. 20%
(w/w) of wax, approx. 5% (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate and approx. 0.5% (w/w) of oleyl alcohol.
-13a-Accordingly, in an embodiment, the present invention further relates to a use of a composition comprising 359. (w/w) of isopropyl myristate, 15t (w/w) of at least one catechol, 24.5% (w/w) of petroleum jelly, 20% (w/w) of wax, 5!k (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate and 0.5%- (w/w) of oleyl alcohol for treating viral skin diseases or tumor diseases caused by papilloma viruses.
The pharmaceutical of the present invention and/or of a pharmaceutical metabolites is used in the treatment of viral skin diseases and/or tumour diseases.
The term pharmaceutical metabolite is to be understood as meaning one or more compounds which arise during use as a result of biological metabolism. These metabolites can be intermediates arising during intermediary metabolism or the end products of metabolism. The metabolites are preferably metabolic products which arise as a result of application to the skin and/or mucosa, in particular hydrolysis products of the compound having the formula (I). Conceivable hydrolysis products can be derived, for example, from radical A
and/or radical B.
Viral skin diseases are understood as being skin diseases which are induced or caused by viruses and/or associated with viral infections. They include, for example, skin diseases such as warts, genital warts, benign tumors of the skin and/or mucosa which are caused by papilloma viruses, for example verrucae plantares, verrucae vulgares, verrucae planae juveniles, epidermodysplasia verruciformis, Condylomata acuminata, Condylomata plana, bowenoid papulosis, papillomas on the larynx and oral mucosa, focal epithelial hyperplasia, herpes labialis, Kaposi's sarcoma, varicella and shingles.
These viral skin diseases and/or tumor diseases are caused by at least one papilloma virus or viruses, in particular human papilloma viruses, such as HPV 1, 2,
Papilloma viruses (HPV) are DNA viruses which infect the epithelial cells of mammals and thereby induce uncontrolled cell growth. There are a very wide variety of papilloma viruses, which infect humans and different animal species. In this connection, all the viral types infect the basal epithelial cells and remain as episomes or integrate their DNA into the host genome.
It has been known for a long time that papilloma viruses cause genital warts (Condyloma acuminata), ordinary and plantar warts, bowenoid papulosis in men and women, and cervical intraepithelial neoplasias in women.
Depending on the method used, the detection rate for HPV is almost 100%. It is in the main HPV 6 and HPV 11 viruses which are found in warts and genital warts (Condyloma acuminata). Since HPV 16 and HPV 18 are principally observed in malignant, desquamative cell carcinomas, as in the case of cancer of the penis and of the uterine cervix, it is generally accepted that HPV 16 and HPV 18 are linked to malignant HPV diseases.
At present, physical methods are predominantly used for treating genital warts caused by human papilloma viruses. These methods include surgical removal, electrocauterization, cryosurgery and laser therapy to mention but a few. An additional medicinal treatment is the use of Podophyllin, 5-Fluorouracil, Bleomycin, Interferon, Imiquimod, etc.
Surgical treatment suffers from the disadvantage that it is very unpleasant for the patient and can lead to further infection. Up until now, a topical use has _ 3 _ involved the risk of side effects since the active compounds employed possess cytotoxic properties or augment the cellular immune defense and can consequently induce local inflammations. This demonstrates that the therapeutic possibilities which have thus far been available are still not satisfactory.
In addition to this, there is the fact that the proportion of recurrences is very high in the case of warts and genital warts and complete healing can only be achieved by means of constant and consistent treatment. For this reason, there is a need for a more reliable and comfortable treatment.
Particularly when treating genital warts, but also in connection with all the other diseases which are caused by the papilloma virus, there is a requirement for a treatment which is easy for the patient to use. For example, a treatment which the patient himself can use at the affected sites and which gives good results in relatively short time, and exhibits only few or no side effects, would be suitable.
Herpes simplex viruses (HSV) are DNA viruses from the alpha subfamily Herpetoviridae. They are divided into two groups, i.e. HSV 1, termed the oral strain, and HSV 2, termed the genital strain. Herpes simplex viruses penetrate, as a nucleocapsid, into the nerve endings and, using the axonal flow, reach the appurtenant ganglia. They are transmitted by smear and droplet infection from herpes lesions or by healthy chronic carriers. Following a primary infection, the viruses can be reactivated once again, symptomatically or asymptomatically, by irritation, for example due to fever, trauma or radiation, of latently infected neurons. This reactivation depends, in particular, on the defensive condition of the body taken as a whole.
Herpes simplex viruses can transform cells neoplastically in animals and in cell cultures. The possibility of an interaction between type 2 herpes simplex viruses and the genesis of cervical carcinomas involving type 16 and type 18 human papilloma viruses is presently being discussed.
EP 0 087 161 discloses treating herpes infections by treating them with a mixture consisting of isopropyl myristate and small quantities of 4-{lower alkyl}-2,6-(bis-tert-butyl)phenol containing 2,6-(bis-tert-butyl)-4-hydroxytoluene or 4-(lower alkyl)-2,6-(bis-tert-butyl)phenol.
EP 0 842 660 describes a pharmaceutical composition for treating genital warts which are caused by human papilloma viruses. The composition which is described comprises catechols from tea extracts (Camellia sinensis), predominantly (-)-epigallocatechol-gallate in the form of an ointment or a suppository.
An object of the present invention is therefore to find additional effective antiviral substances and formulations which are suitable for treating viral skin diseases and/or tumor diseases which are caused by papilloma viruses and/or herpes viruses.
It has now been found, surprisingly, that a pharmaceutical which comprises,a compound according to the invention of the formula (I) as the pharmaceuticall.y active compound is suitable for treating viral skin diseases and/or tumor diseases.
The present invention consequently relates to a pharmaceutical which comprises a compound of the formula (I) as the pharmaceutically active compound, A - B
(I) where A is a radical of the formula (II) Ri (II) and B is a radical of the formula (III) (III), and R1 is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl radical, preferably a C11-C15 alkyl, alkylene or alkynyl radical, in particular a C11-C13 alkyl, alkylene or alkynyl radical, especially a C13-alkyl radical, and R2 is, independent of each other, an unbranched or branched C1-C8 alkyl alkylene or alkynyl radical, preferably a C1-C6 alkyl, alkylene or alkynyl radical, in particular a C2-C4 alkyl, alkylene or alkynyl radical, especially a C3 alkyl radical, a-[CH2- (CH2) m O]õ-H radical where n = 1 to 10, preferably n = 1 to 5, m = 1 to 5, preferably m = 1 to 3, a -CH2- [CH- (OH) ] p- (CH2- (R3) ] radical, where R3 is, independent of each other, a hydrogen or a hydroxyl radical, p = 1 to 7, preferably p= 1 to 4, a pentose radical or a hexose radical.
- 5a -The invention further relates to a use of a compound of the formula (I) A - B
(I) and at least one catechol of the formula (IV) OH
HO O OH
URa R
(IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) oN
OH
O
OH
(V) characterized in that in formula (I) A is a radical of the formula (II) l I
Ri (II) -5b-and B is a radical of the formula (III) (III) , and Rl is a C13-alkyl radical, R2 is selected from:
(a) an unbranched or branched C1-C8alkyl, alkylene or alkynyl radical, (b) a -[CHz-(CH2) m-0] n-H radical, wherein n = 1 to 10 and m= 1 to 5, (c) a -CH2- [CH- (OH) ] p- (CHz- (R3) ] radical, wherein R3 is selected from a hydrogen and a hydroxyl radical, and p= 1 to 7, (d) a pentose radical, and (e) a hexose radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
The invention further relates to a use of a composition comprising a compound of the formula (I) A-B
(I) and at least one catechol of the formula (IV) OH
HO OH
H
(IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) O}l OH
OH
(V) characterized in that in formula (I) A is a radical of the formula (II) il Ri (II) and B is a radical of the formula (III) (III), and -5d-R1 is an unsubstituted or substituted C13-alkyl radical, R2 is an unsubstituted or substituted, unbranched or branched, Cl-Csalkyl, alkylene or alkynyl radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
In this connection, the radical R1 and/or the radical R2 can, independent of each other, be substituted by a halogen, preferably fluorine and/or chlorine, or an unbranched or branched C1.-C6 alkyl, alkylene or alkynyl radical, preferably a C1-C3 alkyl, alkylene or alkynyl radical, in particular a methyl radical.
In this connection, the radical A of the compound (I) can, for example, be derived from hexanoic acid (caproic acid), heptanoic acid, octanoic acid (caprylic acid), nonanoic acid, decanoic acid (capric acid), undecanoic acid, dodecanoic acid (lauric acid), tridecanoic acid, tetradecanoic acid (myristic acid), pentadecanoic acid, hexadecanoic acid (palmitic acid), heptadecanoic acid, octadecanoic acid (stearic acid), nonadecanoic acid, eicosanoic acid, heneicosanoic acid, oleic acid, linoleic acid, linolenic acid and/or arachidonic acid, preferably from caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid and/or arachidonic acid, particularly preferably from myristic acid.
The radical B of the compound (I) can, for example, be derived from an unbranched or branched C1-C8 alkyl alcohol, in particular ethanol, propanol, isopropanol, n-butanol, tert-butanol, particularly preferably isopropanol, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, polyglycerol, a pentose sugar, such as arabitol, adonitol and xylitol, or a hexose sugar, such as sorbitol, mannitol or dulcitol, preferably from ethanol, propanol, isopropanol, butanol, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, polyglycerol, arabitol, adonitol, xylitol, sorbitol, mannitol and/or dulcitol.
The compound (I) is preferably isopropyl laureate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, ethyl myristate, propyl myristate, butyl myristate and/or ethyl oleate, in particular isopropyl myristate.
In another preferred embodiment, the compound (I) is a hydrophobic compound. According to the present invention, a hydrophobic compound is understood as being a compound whose solubility in water is at most approx. 0.2 mg/ml, in particular at most approx.
0.1 mg/ml.
The pharmaceutical comprises, for example, at least approx. 5% - 75% (w/w), preferably at least approx. 10%
- 60% (w/w), in particular at least approx. 25% - 55%
(w/w) , and especially at least approx. 35 0- 50 0(w/w) of the compound of the formula (I).
In this connection, the pharmaceutical according to the invention can also contain one or more additional pharmaceutical active compounds as a combination preparation for use which is simultaneous, separate or staggered in time. In this context, preference is given to employing, as additional pharmaceutical active compounds, those compounds which can be used for treating viral skin diseases and/or tumor diseases, such as podophyllin, 5-fluorouracil, bleomycin, interferon or imiquimod, and/or mixtures which comprise at least one catechol.
In a preferred embodiment, the additional pharmaceutical active compound is an amphiphilic or amphipathic active compound. An amphiphilic or amphipathic active compound is understood as being an active compound which is composed of two functional moieties, in particular one hydrophilic moiety and one lipophilic moiety. This property might, in particular, be able to facilitate the passage of the substance through the skin and achieve an improved effect. In this connection, the improved effect may be attributable, for example, to a longer dwell time at the desired site or to a reduction in the dose of the active compound.
In a further preferred embodiment, the additional pharmaceutical active compound comprises at least one catechol of the formula (IV) Uti tio o (IV) in which R3 is -H or -OH, and R4 is -H or a group of the formula (V) OH
OH
O
OH
(V) The catechols which are added in this connection may be obtained either synthetically or from natural sources.
The natural sources which may especially be mentioned are tea plants. In this context, the natural constituents may bepresent in differing concentrations depending on the species and variety. In this connection, the catechols which are employed are preferably isolated from Camellia sinensis, Camellia asamica, Camellia bohea, Camellia chinensis or Camellia oleosa. All the components of tea plants, in particular the leaves, can be used for isolating the catechols.
The catechols which are employed are preferably isolated from a tea extract.
The catechols which are employed in the present invention are preferably epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, gallocatechol and gallocatechol gallate, in particular (-)-epicatechol, (-)-epicatechol gallate, epigallocatechol, (-)-epigallocatechol gallate, (+)-gallocatechol and (-)-gallocatechol gallate.
The catechols can be used both individually and in the form of mixtures having different compositions. A
catechol mixture contains approx. 2-20% (w/w), preferably approx. 4-15% (w/w), in particular approx.
10-11% (w/w) of (-)-epicatechol, approx. 2-20% (w/w), preferably approx. 5-15% (w/w), in particular approx.
5-7% (w/w) of (-)-epicatechol gallate, approx. 1-25%
(w/w), preferably approx. 3-15% (w/w), in particular approx. 5-7% (w/w) of (-)-epigallocatechol, approx. 40-75% (w/w), preferably approx. 57-67% (w/w), in particular approx. 61-66% (w/w) of (-)-epigallocatechol gallate, approx. 0.05-5% (w/w), preferably approx. 0.1-1% (w/w), in particular approx. 0.1-0.6% (w/w) of (+)-gallocatechol and/or approx. 0.5-20% (w/w), preferably approx. 1-10% (w/w), in particular approx. 1-5% (w/w) of (-)-gallocatechol gallate.
In a preferred embodiment, the catechol mixture is composed of approx. 5.9% (w/w) of (-)-epicatechol, approx. 12.6% (w/w) of (-)-epicatechol gallate, approx.
17.6% (w/w) of (-)-epigallocatechol, approx. 53.9%
(w/w) of (-)-epigallocatechol gallate and/or approx.
1.4% (w/w) of (-)-gallocatechol. A composition of this nature is known under the name Polyphenon 100.
In a particularly preferred embodiment, the catechol mixture is composed of approx. 10.8% (w/w) of (-)-epicatechol, approx. 6.5% (w/w) of (-)-epicatechol gallate, approx. 9.2% (w/w) of (-)-epigallocatechol, approx. 54.8% (w/w) of (-)-epigallocatechol gallate and/or approx. 4.0% (w/w) of (-)-gallocatechol gallate.
A composition of this nature is known under the name Polyphenon E.
The pharmaceutical according to the invention comprises, for example, approx. 1-30% (w/w), preferably approx. 2-20% (w/w) and, in particular, approx. 15-18%
(w/w) of a catechol and at least approx. 5-90% (w/w), preferably at least approx. 10-70% (w/w), in particular at least approx. 25-60% (w/w) and, especially, at least approx. 35-50% (w/w) of the compound (I).
The familiar methods of pharmaceutical technology are used, in a customary manner, for preparing pharmaceuticals which comprise one or more compounds according to the invention and/or for using these pharmaceuticals in the application according to the invention. For this, the active compounds are worked up, together with suitable, pharmaceutically acceptable auxiliary substances and carrier substances, into the medicinal forms which are suitable for the different indications and sites of administration. In this context, the pharmaceuticals can be prepared such that the rate of release in each case desired, for example a rapid accumulation and/or a delayed-release or depot effect, is achieved.
Customary emulsions, gels, ointments, creams of the mixed-phase or amphiphilic emulsion systems (oil/water-' - 11 -water/oil mixed phase), and also liposomes and transfersomes or plasters, preferably ointments and creams, particularly preferably an ointment, may be mentioned for conventional application to the skin or mucosa. The active compound is preferably applied locally in the region in which there is a skin or mucosal change and/or disease.
In addition to the known uses on the skin and/or mucosa, the following are suitable for use as special pharmaceutical preparations which can be administered topically, locally or regionally: emulsions, creams, ointments, effervescent tablets or suppositories which can be administered genitally, vaginally or rectally, in particular genitally and vaginally. Rectal capsules can also be prepared on the basis of gelatin or other carrier substances. Suitable suppository bases are hardened fats, such as Witepsol , Massa Estarium , Novata , coconut butter, glycerol/gelatin pastes, glycerol/soap gels and polyethylene glycols.
Examples of suitable auxiliary and/or carrier substances are sodium alginate, as a gelatinizing agent for preparing a suitable base, or cellulose derivatives, such as guar or xanthan gum, inorganic gelatinizing agents, such as aluminum hydroxide or bentonites (what are termed thixotropic gel-formers), polyacrylic acid derivatives, such as Carb.opol , polyvinylpyrrolidone, microcrystalline cellulose and carboxymethylcellulose. Amphiphilic low molecular weight and higher molecular weight compounds, and also phospholipids, are also suitable. The gels can be present either as water-based hydrogels or as hydrophobic organogels, for example based on mixtures of low and high molecular weight paraffin hydrocarbons and vaselineT"'. The hydrophilic organogels can be prepared, for example, on the basis of high molecular weight polyethylene glycols. These gelatinous forms are washable. However, the organogels which are preferred are the hydrophobic organogels. Particular preference is given to hydrophobic auxiliary substances and additives, such as petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate and propylene glycol monopalmitostearate. It is, of course, likewise possible to add skin-sedating and/or inflammation-inhibiting additives which are known to the skilled person, such as synthetically prepared active compounds and/or extracts and/or active compounds from medicinal plants, in particular bisobolol and panthenol. It is furthermore also possible to add dyes, for example yellow and/or red iron oxide and/or titanium dioxide for the purpose of matching as regards color.
Emulsifiers which can be employed are anionic, cationic or neutral surfactants, for example alkali metal soaps, metal soaps, amine soaps, sulfonated compounds, invert soaps, higher fatty alcohols, partial fatty acid esters of sorbitan and polyoxyethylene sorbitan, e.g. lanette types, wool wax, lanolin or other synthetic products for preparing the oil/water and/or water/oil emulsions.
It is possible to use vaselineT"', natural or synthetic waxes, fatty acids, fatty alcohols, fatty acid esters, for example as monoglycerides, diglycerides or triglycerides, paraffin oil or vegetable oils, hydrogenated castor oil or coconut oil, hog fat, synthetic fats, for example based on, caprylic acid, capric acid, lauric acid or stearic acid, such as Softisan , or triglyceride mixtures, such as Miglyol , can be used as lipids, in the form of fatty and/or oleaginous and/or waxy components for preparing the ointments, creams or emulsions.
It is possible to use, for example, osmotically active acids and alkaline solutions, for example hydrochloric acid, citric acid, sodium hydroxide solution, potassium hydroxide solution, sodium hydrogen carbonate, and, in addition, buffer systems, such as citrate, phosphate, tris buffer or triethanolamine, for adjusting the pH.
It is possible to add preservatives as well, such as methyl benzoate or propyl benzoate (parabens) or sorbic acid, for increasing the stability.
Pastes, powders and solutions may be mentioned as additional forms which can be applied topically. As consistency-imparting bases, the pastes frequently contain hydrophobic and hydrophilic auxiliary substances, preferably, however, hydrophobic auxiliary substances containing a very high proportion of solids.
In order to increase dispersity, and also flowability and slipperiness, and also to prevent agglomerates, the powders or topically applicable powders can, for example, contain starch species, such as wheat or rice starch, flame-dispersed silicon dioxide or siliceous earth, which also serve as diluent.
The medicinal forms which are in each case suitable can be produced on the basis of pharmaceutico-physical principles in conformity with formulation guidelines and methods known to a skilled person.
The pharmaceutical according to the invention preferably comprises approx. 35% (w/w) of isopropyl myristate, approx. 15% (w/w) of at least one catechol, approx. 24.5% (w/w) of petroleum jelly, approx. 20%
(w/w) of wax, approx. 5% (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate and approx. 0.5% (w/w) of oleyl alcohol.
-13a-Accordingly, in an embodiment, the present invention further relates to a use of a composition comprising 359. (w/w) of isopropyl myristate, 15t (w/w) of at least one catechol, 24.5% (w/w) of petroleum jelly, 20% (w/w) of wax, 5!k (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate and 0.5%- (w/w) of oleyl alcohol for treating viral skin diseases or tumor diseases caused by papilloma viruses.
The pharmaceutical of the present invention and/or of a pharmaceutical metabolites is used in the treatment of viral skin diseases and/or tumour diseases.
The term pharmaceutical metabolite is to be understood as meaning one or more compounds which arise during use as a result of biological metabolism. These metabolites can be intermediates arising during intermediary metabolism or the end products of metabolism. The metabolites are preferably metabolic products which arise as a result of application to the skin and/or mucosa, in particular hydrolysis products of the compound having the formula (I). Conceivable hydrolysis products can be derived, for example, from radical A
and/or radical B.
Viral skin diseases are understood as being skin diseases which are induced or caused by viruses and/or associated with viral infections. They include, for example, skin diseases such as warts, genital warts, benign tumors of the skin and/or mucosa which are caused by papilloma viruses, for example verrucae plantares, verrucae vulgares, verrucae planae juveniles, epidermodysplasia verruciformis, Condylomata acuminata, Condylomata plana, bowenoid papulosis, papillomas on the larynx and oral mucosa, focal epithelial hyperplasia, herpes labialis, Kaposi's sarcoma, varicella and shingles.
These viral skin diseases and/or tumor diseases are caused by at least one papilloma virus or viruses, in particular human papilloma viruses, such as HPV 1, 2,
3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19-29, 31, 32, 34, 36-38, 46-50, 56, 58, by at least one herpes virus or herpes viruses, such as herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus or human herpes virus, such as 1, 2, 3, 4, 7 or 8.
The figures and the following examples are intended to clarify the invention without restricting it. Skilled persons can modify the invention appropriately, within the bounds of customary ability, without departing from the protective scope.
Examples Clinical study for comparing an ointment and a cream containing isopropyl myristate 93 patients (in each case divided equally into men and women) took part in a multicenter clinical study which was carried out at a total of 30 different centers in Germany and Russia. The study was randomized and performed double-blind. The study examined the clinical efficacy of two different formulations of isopropyl myristate (an ointment and a cream) in the treatment of external genital warts.
The formulations which were tested had the following compositions:
Cream 1:
Substance Quantity (in % w/w) Cera alba 6.996 Monomuls 2.798 Lameform TGI 5.598 Cetiol V 6.996 Isopropyl myristate 13.992 Tocopherol 0.699 Cont roxT"' KS 0.066 Glycerol 6.996 Disodium EDTA 0.001 Magnesium sulfate 1.399 D-Panthenol 0.699 Purified water 53.678 Red Iron Oxide* 0.025 Yellow Iron Oxide* 0.054 * The dyes were added for matching as regards color.
Ointment 1:
Substance Quantity (in % w/w) White Petrolatum, USP 34.023 White Wax, NF 25.000 Isopropyl Myristate, NF 35.000 Oleyl Alcohol, NF 0.500 Propylene Glycol Monostearate, NF 5.000 Red Iron Oxide* 0.022 Yellow Iron Oxide* 0.055 Titanium Dioxide, USP* 0.400 * The dyes were added for matching as regards color.
The patients applied the topical study medication three times daily or until the genital warts had completely healed or for a maximum of twelve weeks.
The following data were collected during the study:
Complete healing (in %) Cream 1 Ointment 1 Male 39.1 42.1 Female 35.0 33.3 Partial healing (in %); this corresponds to at least 75% healing based on the total area of the genital warts.
Cream 1 Ointment 1 Male 43.5 63.2 Female 50.0 52.4 The results of the study show that a surprisingly high degree of complete healing, or partial healing, takes place as compared with the placebo values from similar studies using different formulations, in association with which the spontaneous regression of genital warts is approx. 20% in the case of women and approx. 5% in the case of men (AldaraTM (Imiquimod) Cream, 5% Product Monograph, marketed by 3M Pharmaceuticals, Northridge, CA, Beutner KR et al. (1998) J Am Acad Dermatol 38, 230-9, Edwards L et al. (1998) Arch Dermatol 134 (1);
25-30).
This therapeutic effect is attributed to the isopropyl myristate, an antiviral effect of which has consequently been demonstrated for the first time.
Clinical study for comparing an ointment and a cream containing isopropyl myristate and Polyphenon E
272 patients (equally divided between men and women in each case) took part in a multicenter clinical study which was carried out at a total of 30 different centers in Germany and Russia. The study was randomized and performed double-blind. The study examined the clinical efficacy of two different formulations of isopropyl myristate and Polyphenon E (an ointment and a cream), as against the formulations from Example 1 containing isopropyl myristate, in the treatment of external genital warts.
The Polyphenon E-containing formulations which were tested had the following compositions:
Cream 2:
Substance Quantity (in % w/w) Polyphenon E 10.000 Cera alba 5.263 Monomuls 2.105 Lameform TGI 4.211 Cetiol V 5.263 Isopropyl myristate 10.526 Tocopherol 0.526 ControxT"' KS 0.050 Glycerol 5.263 Disodium EDTA 0.001 Magnesium sulfate 1.053 D-Panthenol 0.526 Purified water 55.213 Ointment 2:
Substance Quantity (in % w/w) Polyphenon E 15.000 White Petrolatum, USP 24.500 White Wax, NF 20.000 Isopropyl Myristate, NF 35.000 Oleyl Alcohol, NF 0.500 Propylene Glycol Monostearate, NF 5.000 The patients applied the topical study medication three times daily or until the genital warts had completely healed or for a maximum of twelve weeks.
During the study, the following data were collected:
Complete healing (in %) Cream 1 Cream 2 Ointment 1 Ointment 2 Male 39.1 53.9 42.1 61.0 Female 35.0 39.5 133.3 56.8 Partial healing (? 75% in %) Cream 1 Cream 2 Ointment 1 Ointment 2 Male 43.5 64.2 63.2' 80.5 Female 50.0 47.4 52.4 81.1 Analysis of the study shows that, when comparing ointment 1 and cream 1, on the one hand, and ointment 2 and cream 2, on the other hand, the combination of isopropyl myristate and Polyphenon E leads to a surprising increase in the efficacy of the pharmaceutical.
If the efficacy of ointment 2 is now compared with that of cream 2, it then becomes evident that ointment 2 is markedly more effective than cream 2. This suggests a synergistic effect between the Polyphenori E and the isopropyl myristate in the hydrophobic ointment.
As a result of this synergistic effect, the individual active compounds in the formulation can, in order to achieve the same effect, be employed in substantially smaller quantities than the corresponding individual components. Consequently, the use of this synergistic formulation has advantages not only with regard to the effect but also with regard to the cost of preparing this formulation, something which in turn can have a positive effect on the cost of treating the patient.
The figures and the following examples are intended to clarify the invention without restricting it. Skilled persons can modify the invention appropriately, within the bounds of customary ability, without departing from the protective scope.
Examples Clinical study for comparing an ointment and a cream containing isopropyl myristate 93 patients (in each case divided equally into men and women) took part in a multicenter clinical study which was carried out at a total of 30 different centers in Germany and Russia. The study was randomized and performed double-blind. The study examined the clinical efficacy of two different formulations of isopropyl myristate (an ointment and a cream) in the treatment of external genital warts.
The formulations which were tested had the following compositions:
Cream 1:
Substance Quantity (in % w/w) Cera alba 6.996 Monomuls 2.798 Lameform TGI 5.598 Cetiol V 6.996 Isopropyl myristate 13.992 Tocopherol 0.699 Cont roxT"' KS 0.066 Glycerol 6.996 Disodium EDTA 0.001 Magnesium sulfate 1.399 D-Panthenol 0.699 Purified water 53.678 Red Iron Oxide* 0.025 Yellow Iron Oxide* 0.054 * The dyes were added for matching as regards color.
Ointment 1:
Substance Quantity (in % w/w) White Petrolatum, USP 34.023 White Wax, NF 25.000 Isopropyl Myristate, NF 35.000 Oleyl Alcohol, NF 0.500 Propylene Glycol Monostearate, NF 5.000 Red Iron Oxide* 0.022 Yellow Iron Oxide* 0.055 Titanium Dioxide, USP* 0.400 * The dyes were added for matching as regards color.
The patients applied the topical study medication three times daily or until the genital warts had completely healed or for a maximum of twelve weeks.
The following data were collected during the study:
Complete healing (in %) Cream 1 Ointment 1 Male 39.1 42.1 Female 35.0 33.3 Partial healing (in %); this corresponds to at least 75% healing based on the total area of the genital warts.
Cream 1 Ointment 1 Male 43.5 63.2 Female 50.0 52.4 The results of the study show that a surprisingly high degree of complete healing, or partial healing, takes place as compared with the placebo values from similar studies using different formulations, in association with which the spontaneous regression of genital warts is approx. 20% in the case of women and approx. 5% in the case of men (AldaraTM (Imiquimod) Cream, 5% Product Monograph, marketed by 3M Pharmaceuticals, Northridge, CA, Beutner KR et al. (1998) J Am Acad Dermatol 38, 230-9, Edwards L et al. (1998) Arch Dermatol 134 (1);
25-30).
This therapeutic effect is attributed to the isopropyl myristate, an antiviral effect of which has consequently been demonstrated for the first time.
Clinical study for comparing an ointment and a cream containing isopropyl myristate and Polyphenon E
272 patients (equally divided between men and women in each case) took part in a multicenter clinical study which was carried out at a total of 30 different centers in Germany and Russia. The study was randomized and performed double-blind. The study examined the clinical efficacy of two different formulations of isopropyl myristate and Polyphenon E (an ointment and a cream), as against the formulations from Example 1 containing isopropyl myristate, in the treatment of external genital warts.
The Polyphenon E-containing formulations which were tested had the following compositions:
Cream 2:
Substance Quantity (in % w/w) Polyphenon E 10.000 Cera alba 5.263 Monomuls 2.105 Lameform TGI 4.211 Cetiol V 5.263 Isopropyl myristate 10.526 Tocopherol 0.526 ControxT"' KS 0.050 Glycerol 5.263 Disodium EDTA 0.001 Magnesium sulfate 1.053 D-Panthenol 0.526 Purified water 55.213 Ointment 2:
Substance Quantity (in % w/w) Polyphenon E 15.000 White Petrolatum, USP 24.500 White Wax, NF 20.000 Isopropyl Myristate, NF 35.000 Oleyl Alcohol, NF 0.500 Propylene Glycol Monostearate, NF 5.000 The patients applied the topical study medication three times daily or until the genital warts had completely healed or for a maximum of twelve weeks.
During the study, the following data were collected:
Complete healing (in %) Cream 1 Cream 2 Ointment 1 Ointment 2 Male 39.1 53.9 42.1 61.0 Female 35.0 39.5 133.3 56.8 Partial healing (? 75% in %) Cream 1 Cream 2 Ointment 1 Ointment 2 Male 43.5 64.2 63.2' 80.5 Female 50.0 47.4 52.4 81.1 Analysis of the study shows that, when comparing ointment 1 and cream 1, on the one hand, and ointment 2 and cream 2, on the other hand, the combination of isopropyl myristate and Polyphenon E leads to a surprising increase in the efficacy of the pharmaceutical.
If the efficacy of ointment 2 is now compared with that of cream 2, it then becomes evident that ointment 2 is markedly more effective than cream 2. This suggests a synergistic effect between the Polyphenori E and the isopropyl myristate in the hydrophobic ointment.
As a result of this synergistic effect, the individual active compounds in the formulation can, in order to achieve the same effect, be employed in substantially smaller quantities than the corresponding individual components. Consequently, the use of this synergistic formulation has advantages not only with regard to the effect but also with regard to the cost of preparing this formulation, something which in turn can have a positive effect on the cost of treating the patient.
Claims (50)
1. Use of a composition comprising a compound of the formula (I) A - B
(I) and at least one catechol of the formula (IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) characterized in that in formula (I) A is a radical of the formula (II) and B is a radical of the formula (III) (III), and R1 is an unsubstituted or substituted C13-alkyl radical, R2 is an unsubsituted or substituted, unbranched or branched, C1-C8alkyl, alkylene or alkynyl radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
(I) and at least one catechol of the formula (IV) wherein in formula (IV) R3 is -H or -OH, and R4 is -H or a group of the formula (V) characterized in that in formula (I) A is a radical of the formula (II) and B is a radical of the formula (III) (III), and R1 is an unsubstituted or substituted C13-alkyl radical, R2 is an unsubsituted or substituted, unbranched or branched, C1-C8alkyl, alkylene or alkynyl radical, for treating viral skin diseases or tumor diseases caused by papilloma viruses.
2. The use of claim 1, wherein the unbranched or branched C1-C8alkyl, alkylene or alkynyl radical is a C1-C6alkyl, alkylene or alkynyl radical.
3. The use of claim 1 or 2, wherein the unbranched or branched C1-C8alkyl, alkylene or alkynyl radical is a C2-C4alkyl, alkylene or alkynyl radical.
4. The use of any one of claims 1-3, wherein the unbranched or branched C1-C8alkyl, alkylene or alkynyl radical is a C3alkyl radical.
5. The use any one of claims 1-4, characterized in that, independent of each other, the radical R1 and the radical R2 are substituted by a halogen or an unbranched or branched C1-C6alkyl, alkylene or alkynyl radical.
6. The use of claim 5, wherein the halogen is fluorine or chlorine.
7. The use of claim 5, wherein the unbranched or branched C1-C6alkyl, alkylene or alkynyl radical is a C1-C3alkyl, alkylene or alkynyl radical.
8. The use of claim 5 or 7, wherein the unbranched or branched C1-C6alkyl, alkylene or alkynyl radical is a methyl radical.
9. The use of any one of claims 1-8, characterized in that the radical A is a derivative of myristic acid.
10. The use of any one of claims 1-9, characterized in that the radical B is a derivative of ethanol, propanol, isopropanol, ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, glycerol, polyglycerol, arabitol, adonitol, xylitol, sorbitol, mannitol or dulcitol.
11. The use of any one of claims 1-10, characterized in that the compound of formula (I) is isopropyl myristate.
12. The use of any one of claims 1-11, characterized in that the use comprises use of a composition comprising at least 5%-75% (w/w) of the compound of formula (I).
13. The use of claim 12, characterized in that the composition comprises at least 10-60% (w/w) of the compound of formula (I).
14. The use of claim 12, characterized in that the composition comprises at least 25-55% (w/w) of the compound of formula (I).
15. The use of claim 12, characterized in that the composition comprises at least 35-50% (w/w) of the compound of formula (I).
16. The use of any one of claims 1-15, further comprising a use of one or more additional pharmaceutical active compounds.
17. The use of claim 16, characterized in that the additional pharmaceutical active compound is amphiphilic.
18. The use of any one of claims 1-17, characterized in that the catechol is selected from epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, gallocatechol and gallocatechol gallate.
19. The use of claim 18, characterized in that catechol is selected from (-)-epicatechol, (-)-epicatechol gallate, (-)-epigallocatechol, (-)- epigallocatechol gallate, (+)-gallocatechol and (-)-gallocatechol gallate.
20. The use of claim 18 or 19, characterized in that the catechols are present in the form of a mixture comprising 2-20% (w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
21. The use of claim 20, wherein the mixture comprises 4-15%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
22. The use of claim 20, wherein the mixture comprises 10-11%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
23. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 5-15% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 5-15% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
24. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 5-7% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 5-7% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
25. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 3-15% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 3-15% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
26. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 5-7% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 5-7% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
27. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 57-67% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 57-67% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
28. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 61-66% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 61-66% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
29. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
30. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.1-0.6% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.1-0.6% (w/w) of (+)-gallocatechol or 0.5-20% (w/w) of (-)-gallocatechol gallate.
31. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 1-10% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 1-10% (w/w) of (-)-gallocatechol gallate.
32. The use of claim 20, wherein the mixture comprises 2-20%
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 1-5% (w/w) of (-)-gallocatechol gallate.
(w/w) of (-)-epicatechol, 2-20% (w/w) of (-)-epicatechol gallate, 1-25% (w/w) of (-)-epigallocatechol, 40-75% (w/w) of (-)-epigallocatechol gallate, 0.05-5% (w/w) of (+)-gallocatechol or 1-5% (w/w) of (-)-gallocatechol gallate.
33. The use of any one of claims 1-20, characterized in that catechols are present in the form of a mixture which comprises 10.8% (w/w) of (-)-epicatechol, 6.5%(w/w) of (-)-epicatechol gallate, 9.2% (w/w) of (-)-epigallocatechol, 54.8% (w/w) of (-)-epigallocatechol gallate and 4.0% (w/w) of (-)-gallocatechol gallate.
34. The use of any one of claims 1-33, characterized in that said catechols of the formula (IV) are isolated from a tea extract.
35. The use of any one of claims 1-11, characterized in that the use comprises use of a composition comprising 1-30% (w/w) of a catechol of formula (IV), at least 5-90% (w/w) of the compound of formula (I), and further additives or auxiliary compounds.
36. The use of claim 35, characterized in that the composition comprises 2-20% (w/w) of a catechol of formula (IV) and at least 5-90% (w/w) of the compound of formula (I).
37. The use of claim 35, characterized in that the composition comprises 15-18% (w/w) of a catechol of formula (IV) and at least 5-90% (w/w) of the compound of formula (I).
38. The use of claim 35, characterized in that the composition comprises 1-30% (w/w) of a catechol of formula (IV) and at least 10-70% (w/w) of the compound of formula (I).
39. The use of claim 35, characterized in that the composition comprises 1-30% (w/w) of a catechol of formula (IV) and at least 25-60% (w/w) of the compound of formula (I).
40. The use of claim 35, characterized in that the composition comprises 1-30% (w/w) of a catechol of formula (IV) and at least 35-50% (w/w) of the compound of formula (I).
41. The use of any one of claims 1-34, characterized in that the compound of formula (I) is hydrophobic.
42. The use of any one of claims 35-40, characterized in that the compound of formula (I) is hydrophobic.
43. The use of any one of claims 1-34 and 41, which comprises further additives or auxiliary compounds.
44. The use of any one of claims 35-40 and 43, characterized in that the additives or auxiliary compounds are hydrophobic.
45. The use of claim 44, characterized in that the additives or auxiliary compounds are selected from petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate and propylene glycol monopalmitostearate.
46. Use of a composition comprising 35% (w/w) of isopropyl myristate, 15% (w/w) of at least one catechol, 24.5% (w/w) of petroleum jelly, 20% (w/w) of wax, 5% (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate and 0.5% (w/w) of oleyl alcohol for treating viral skin diseases or tumor diseases caused by papilloma viruses.
47. The use of any one of claims 1-46, characterized in that the viral skin diseases or tumor diseases are caused by human papilloma viruses.
48. The use of any one of claims 1-47, characterized in that the skin diseases are warts, genital warts, or benign tumors of the skin or mucosa caused by papilloma viruses.
49. The use of any one of claims 1-48, characterized in that the use is topical.
50. The use of claim 49, wherein the topical use is genital or vaginal.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33170501P | 2001-11-19 | 2001-11-19 | |
| DE10156794.4 | 2001-11-19 | ||
| US60/331,705 | 2001-11-19 | ||
| DE10156794A DE10156794B4 (en) | 2001-11-19 | 2001-11-19 | Medicines for the treatment of warts |
| PCT/EP2002/012919 WO2003043628A1 (en) | 2001-11-19 | 2002-11-18 | Medicament for the treatment of viral skin and tumour diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2466720A1 CA2466720A1 (en) | 2003-05-30 |
| CA2466720C true CA2466720C (en) | 2010-02-09 |
Family
ID=26010614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2466720A Expired - Lifetime CA2466720C (en) | 2001-11-19 | 2002-11-18 | Medicament for the treatment of viral skin and tumour diseases |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7858662B2 (en) |
| EP (2) | EP2055300B1 (en) |
| JP (1) | JP4495459B2 (en) |
| KR (1) | KR100956369B1 (en) |
| CN (1) | CN1323660C (en) |
| AT (1) | ATE417611T1 (en) |
| BR (1) | BRPI0214256B8 (en) |
| CA (1) | CA2466720C (en) |
| CY (1) | CY1108882T1 (en) |
| DE (2) | DE122009000073I1 (en) |
| DK (1) | DK1448186T3 (en) |
| ES (1) | ES2319626T3 (en) |
| HK (2) | HK1073788A1 (en) |
| IL (2) | IL161625A0 (en) |
| MX (1) | MXPA04004532A (en) |
| PT (1) | PT1448186E (en) |
| RU (1) | RU2302861C3 (en) |
| WO (1) | WO2003043628A1 (en) |
| ZA (1) | ZA200403287B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1323660C (en) | 2001-11-19 | 2007-07-04 | 麦迪金股份公司 | Medicament for the treatment of viral skin and tumour diseases |
| ITMI20030210A1 (en) * | 2003-02-07 | 2004-08-08 | Res & Innovation Soc Coop A R L | ENDOCANNABINOID-SIMILAR COMPOUNDS AND THEIR USE |
| US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| US20050079235A1 (en) * | 2003-10-09 | 2005-04-14 | Eggert Stockfleth | Use of a polyphenol for the treatment of actinic keratosis |
| AR045865A1 (en) | 2003-10-09 | 2005-11-16 | Medigene Ag | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROSE OR PRE-CANCERAL SKIN INJURY |
| KR100665315B1 (en) | 2004-03-25 | 2007-01-09 | 한국원자력연구소 | New gallic acid-conjugated linoleic acid fatty ester, the preparation method thereof and composition containing the same |
| EP1898900B1 (en) | 2005-03-10 | 2011-06-08 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
| US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
| US8476319B2 (en) | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
| EP2179722A1 (en) * | 2008-10-24 | 2010-04-28 | Heinrich-Pette-Institut für experimentelle Virologie und Immunologie | Topical formation for preventing sexual transmission of viral infection |
| CN102949387B (en) * | 2011-08-19 | 2017-03-01 | 奥古斯塔大学研究所公司 | For treating compositionss and the method for herpes simplex virus |
| JP5796006B2 (en) * | 2011-12-14 | 2015-10-21 | 有限会社 ワーコム農業研究所 | Antibacterial agent |
| RU2600033C2 (en) * | 2014-10-16 | 2016-10-20 | Юрий Николаевич Родионов | Method of producing substance for destruction of microvasculature of removed skin formation |
| IL254568B2 (en) | 2015-03-19 | 2023-11-01 | Wendy Anne Epstein | Tea catechin for the treatment for female sexual disorders |
| CN107349197A (en) * | 2017-07-13 | 2017-11-17 | 黄冈师范学院 | A kind of application of catechin on the medicine for preparing treatment cutaneous papilloma |
| KR20230149132A (en) | 2022-04-19 | 2023-10-26 | 고려대학교 산학협력단 | Antiviral composition for Epstein-Barr virus comprising catechol compound or derivative thereof as an active ingredient |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002775A (en) * | 1973-07-09 | 1977-01-11 | Kabara Jon J | Fatty acids and derivatives of antimicrobial agents |
| JPS55105677A (en) * | 1979-02-07 | 1980-08-13 | Norin Suisansyo Chiyagiyou Shikenjo | Production of catechins |
| EP0087161A3 (en) * | 1982-02-24 | 1984-04-04 | Key Pharmaceuticals, Inc. | Isopropylmyristate 4-alkyl-2,6-(bis-tert-butyl)-phenol medicament |
| JPS59219384A (en) * | 1983-05-30 | 1984-12-10 | Mitsui Norin Kk | Preparation of natural antioxidant |
| JPS6013780A (en) * | 1983-07-05 | 1985-01-24 | Mitsui Norin Kk | Production of tea catechin compound |
| JPS61238728A (en) * | 1985-04-16 | 1986-10-24 | Mitsui Norin Kk | Complex substance of extract of tea leaf and active aluminum hydroxide |
| SE462894B (en) * | 1985-10-28 | 1990-09-17 | Biogram Ab | MICROCAPPLES, PROCEDURES FOR PREPARING THEREOF AND USING |
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5204089A (en) * | 1989-08-30 | 1993-04-20 | Mitsui Norin Co., Ltd. | Method of preventing the formation or aggrevation of dental plaque and method for reducing cariogenesis |
| JP2727471B2 (en) * | 1989-09-14 | 1998-03-11 | 三井農林株式会社 | Influenza virus infection prevention agent |
| JP2888554B2 (en) * | 1989-09-20 | 1999-05-10 | 三井農林株式会社 | Mycoplasma infection preventive agent |
| US5318986A (en) * | 1989-10-19 | 1994-06-07 | Mitsui Norin Co., Ltd. | Method of inhibiting the activity of α-amylase |
| US5358713A (en) * | 1990-02-23 | 1994-10-25 | Mitsui Norin Co., Ltd. | Method of preventing the transmission of infection caused by methicillin-resistant Staphylococcus aureus |
| JP3019996B2 (en) * | 1990-03-01 | 2000-03-15 | 三井農林株式会社 | Ringworm treatment |
| JPH04253918A (en) | 1991-02-05 | 1992-09-09 | Mitsui Norin Kk | Hyperglycemic inhibitor |
| US5633284A (en) * | 1992-06-08 | 1997-05-27 | Pitmy International N.V. | Nitrous oxide containing dermatological composition |
| US5306486A (en) * | 1993-03-01 | 1994-04-26 | Elizabeth Arden Co., Division Of Conopco, Inc. | Cosmetic sunscreen composition containing green tea and a sunscreen |
| JP3333584B2 (en) * | 1993-04-19 | 2002-10-15 | 三井農林株式会社 | Composition for enhancing acid resistance of teeth |
| JPH07196466A (en) * | 1993-12-29 | 1995-08-01 | Sunstar Inc | Cosmetic composition formulated with tea powder |
| US5670154A (en) * | 1994-01-10 | 1997-09-23 | Mitsui Norin Co., Ltd. | Reducing tyrosinase activity |
| FR2718022B1 (en) * | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Cosmetic or dermatological compositions and their preparation. |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| JP2718653B2 (en) * | 1995-01-31 | 1998-02-25 | 日本配合飼料株式会社 | New egg and egg quality improvement method |
| IT1275905B1 (en) * | 1995-03-14 | 1997-10-24 | Indena Spa | POLYPHENOLIC FRACTIONS OF TEA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM |
| US5888527A (en) * | 1995-05-11 | 1999-03-30 | Matsushita Seiko Co., Ltd. | Gargling cup, antiviral mask, antiviral filter, antifungal, antibacterial, and antiviral filter air cleaner and air-cleaner humidifier |
| GB2300578B (en) * | 1995-05-11 | 1998-01-14 | Matsushita Seiko Kk | Gargling cup,antiviral mask,antiviral filter,antifungal,antibacterial,and antiviral filter air cleaner and air-cleaner-humidifier |
| JPH09132532A (en) * | 1995-09-06 | 1997-05-20 | Mitsui Norin Kk | Enhancement of antimicrobial activity of antibiotic substance |
| US6197806B1 (en) * | 1995-12-20 | 2001-03-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Eliminating agent for activated oxygen and free radicals |
| US6127393A (en) * | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US5804567A (en) * | 1996-07-18 | 1998-09-08 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method of increasing the effectiveness of anti-metabolites |
| US6337320B1 (en) | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
| CA2271843A1 (en) * | 1996-11-14 | 1998-05-22 | Lipomedica Ehf. | Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
| US5968973A (en) * | 1996-11-18 | 1999-10-19 | Cancer Institute (Hospital), Chinese Academy Of Medical Sciences | Method for treating hyperplasia |
| US6197808B1 (en) | 1996-11-18 | 2001-03-06 | Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences | Methods for treating hyperplasia |
| JP3213557B2 (en) * | 1996-11-18 | 2001-10-02 | 三井農林株式会社 | A remedy for condyloma acuminatum containing tea catechin as an active ingredient |
| US20020198161A1 (en) * | 1997-02-20 | 2002-12-26 | Douglas E. Brash | Therapeutic uses of antioxidants |
| JP3202938B2 (en) * | 1997-03-18 | 2001-08-27 | 三井農林株式会社 | Chewing gum and method for producing the same |
| US5910308A (en) * | 1997-03-19 | 1999-06-08 | Sante International Inc. | Herbal extract composition containing gynostemma pentaphyllum, crataegus pinnatifida and camellia sinensis |
| US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| KR100269520B1 (en) * | 1997-07-29 | 2000-10-16 | 구본준 | Thin-film transistor, liquid-crystal display and manufacturing method thereof |
| US6576660B1 (en) * | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
| US6696484B2 (en) * | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US20020006447A1 (en) * | 1998-04-21 | 2002-01-17 | Mitsui Norin Co., Ltd. | Anti-chlamydia agent |
| CA2294207C (en) | 1998-04-21 | 2004-09-21 | Mitsui Norin Co., Ltd. | Anti-chlamydia agent |
| DE19827624A1 (en) * | 1998-06-20 | 1999-12-23 | Beiersdorf Ag | Use of catechols or plant extracts containing them in intensifying natural skin tanning or in stimulating melanogenesis |
| SE9803929D0 (en) | 1998-11-18 | 1998-11-18 | Medivir Ab | Antiviral formulation |
| KR100319973B1 (en) * | 1998-12-05 | 2002-04-22 | 이인수 | Cervical epithelial tumor prophylaxis or treatment composition using green tea catechin as an active ingredient |
| US6210679B1 (en) * | 1999-01-07 | 2001-04-03 | Hauser, Inc. | Method for isolation of caffeine-free catechins from green tea |
| DE19958159A1 (en) * | 1999-12-02 | 2001-06-07 | Degussa | New nucleotide sequences coding for the glk gene |
| DE19962369A1 (en) | 1999-12-23 | 2001-06-28 | Beiersdorf Ag | Composition of ascorbyl compound and catechin, or extract containing it, useful for improving barrier properties of skin |
| US6248341B1 (en) | 2000-01-14 | 2001-06-19 | Color Access, Inc. | Method of treating topical angiogenesis-related disorders |
| US20020031535A1 (en) * | 2000-09-11 | 2002-03-14 | Sheffield Felix H. | Topical formulation to treat skin disorders |
| US6713506B2 (en) * | 2000-10-11 | 2004-03-30 | University Of South Florida | Tea polyphenol esters and analogs thereof for cancer prevention and treatment |
| CN1323660C (en) | 2001-11-19 | 2007-07-04 | 麦迪金股份公司 | Medicament for the treatment of viral skin and tumour diseases |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| US20030166583A1 (en) * | 2002-02-22 | 2003-09-04 | Oliver Yoa-Pu Hu | Dermal cytochrome P450 1A inhibitors and enhancers |
| US6723750B2 (en) * | 2002-03-15 | 2004-04-20 | Allergan, Inc. | Photodynamic therapy for pre-melanomas |
| BRPI0204130B8 (en) | 2002-09-18 | 2021-05-25 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp | gel composition based on pothomorphe umbellata extract, its uses and non-therapeutic cosmetic method. |
| US20040191842A1 (en) * | 2002-12-10 | 2004-09-30 | Medical College Of Georgia Research Institute, Inc. | Chemopreventive and therapeutic aspects of polyphenolic compositions and assays |
| WO2004080293A2 (en) * | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Methods for diagnosing skin lesions |
| AR045865A1 (en) * | 2003-10-09 | 2005-11-16 | Medigene Ag | THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROSE OR PRE-CANCERAL SKIN INJURY |
| US20050079235A1 (en) * | 2003-10-09 | 2005-04-14 | Eggert Stockfleth | Use of a polyphenol for the treatment of actinic keratosis |
-
2002
- 2002-11-18 CN CNB028227506A patent/CN1323660C/en not_active Expired - Lifetime
- 2002-11-18 CA CA2466720A patent/CA2466720C/en not_active Expired - Lifetime
- 2002-11-18 EP EP08021728.4A patent/EP2055300B1/en not_active Expired - Lifetime
- 2002-11-18 EP EP02803380A patent/EP1448186B1/en not_active Expired - Lifetime
- 2002-11-18 RU RU2004118667A patent/RU2302861C3/en active Protection Beyond IP Right Term
- 2002-11-18 DE DE122009000073C patent/DE122009000073I1/en active Pending
- 2002-11-18 PT PT02803380T patent/PT1448186E/en unknown
- 2002-11-18 KR KR1020047006612A patent/KR100956369B1/en active IP Right Grant
- 2002-11-18 JP JP2003545309A patent/JP4495459B2/en not_active Expired - Fee Related
- 2002-11-18 MX MXPA04004532A patent/MXPA04004532A/en active IP Right Grant
- 2002-11-18 US US10/495,889 patent/US7858662B2/en not_active Expired - Fee Related
- 2002-11-18 ES ES02803380T patent/ES2319626T3/en not_active Expired - Lifetime
- 2002-11-18 WO PCT/EP2002/012919 patent/WO2003043628A1/en active IP Right Grant
- 2002-11-18 DE DE50213137T patent/DE50213137D1/en not_active Expired - Lifetime
- 2002-11-18 BR BRPI0214256A patent/BRPI0214256B8/en not_active IP Right Cessation
- 2002-11-18 DK DK02803380T patent/DK1448186T3/en active
- 2002-11-18 IL IL16162502A patent/IL161625A0/en unknown
- 2002-11-18 AT AT02803380T patent/ATE417611T1/en active
-
2004
- 2004-04-26 IL IL161625A patent/IL161625A/en active Protection Beyond IP Right Term
- 2004-04-30 ZA ZA2004/03287A patent/ZA200403287B/en unknown
-
2005
- 2005-07-28 HK HK05106471A patent/HK1073788A1/en not_active IP Right Cessation
-
2009
- 2009-03-17 CY CY20091100293T patent/CY1108882T1/en unknown
- 2009-10-20 HK HK09109657.6A patent/HK1131048A1/en not_active IP Right Cessation
-
2010
- 2010-09-21 US US12/887,250 patent/US9770406B2/en active Active
-
2017
- 2017-08-18 US US15/680,819 patent/US10434059B2/en not_active Expired - Fee Related
-
2019
- 2019-08-19 US US16/543,763 patent/US20200054552A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10434059B2 (en) | Medicament for the treatment of viral skin and tumour diseases | |
| US20170000814A1 (en) | Therapeutic composition | |
| WO1999012545A2 (en) | Medicaments containing acyclovir | |
| ES2569395T3 (en) | Drug containing isopropyl myristate and a catechin | |
| JP2010511723A (en) | Topical pharmaceutical composition | |
| CA2015206A1 (en) | Topical antiviral pharmaceutical composition containing a nonionic surfactant | |
| US20200022933A1 (en) | Surfactants and compositions for treatment of viral skin conditions | |
| CA3100428A1 (en) | Treatments | |
| JPWO2004069261A1 (en) | Method for producing anti-herpesvirus external preparation | |
| KR101818882B1 (en) | Pharmaceutical composition for prevention or treatment of infections caused by herpes virus | |
| US20060009401A1 (en) | Method for treatment and prevention of herpes zoster by topical application | |
| AU2019375206A1 (en) | Teriflunomide topical pharmaceutical compositions | |
| CA2009402A1 (en) | Use of benzydamine and salts thereof for relief of pain associated with herpes viral infections and laser vaporization of condylomata | |
| JPH09143096A (en) | Medicinal composition for viral disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221118 |